StemCutis

StemCutis is a clinical-stage biotechnology company and a subsidiary of Stemedica Cell Technologies, focused on developing allogeneic stem cell therapies for dermatological applications and over-the-counter skin care. The company's core technology utilizes ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under hypoxic conditions, which are designed to enhance homing, engraftment, and the secretion of regenerative growth factors. StemCutis is primarily advancing a Phase I/II clinical program for cutaneous photoaging, combining its stem cell therapy with low-dose fractional laser treatment to promote skin rejuvenation. Additionally, the company holds exclusive licenses to explore indications such as diabetic ulcers, hair loss, burns, and various types of scarring. Headquartered in San Diego, StemCutis leverages its parent company's cGMP-compliant manufacturing capabilities to produce standardized, scalable cell products. The company aims to address the underlying physiological causes of skin aging and damage rather than merely treating symptoms.